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Sjögren’s Syndrome (SjS) is a common chronic autoimmune disease characterized by
the B cell hyperactivation, lymphocyte infiltration, and tissue damage of exocrine glands.
It can also present life-threatening extraglandular manifestations, such as pulmonary and
hepatic involvement, renal inflammation andmarginal zone (MZ) B cell lymphoma. Several
biologic agents have been tested in SjS but none has shown significant efficacy. Here,
we report the effects of Ly9 (CD229) antibody targeting, a cell surface molecule that
belongs to the SLAM family of immunomodulatory receptors, using NOD.H-2h4 mice as
a model of SjS-like disease. Female mice were treated with anti-Ly9 antibody or isotype
control at week 24, when all mice present SjS related autoantibodies, salivary gland
infiltrates, and marginal zone (MZ) B cell pool enlargement. Antibody injection depleted
key lymphocyte subsets involved in SjS pathology such asMZ, B1, and germinal center B
cells in spleen and draining lymph nodes without inducing a general immunosuppression.
Importantly, mice receiving anti-Ly9 mAb showed a reduced lymphocyte infiltrate within
salivary glands. This reduction may be, in part, explained by the down-regulation
of L-selectin and alfa4/beta7 integrin induced by the anti-Ly9 antibody. Furthermore,
levels of anti-nuclear autoantibodies were reduced after anti-Ly9 treatment. These data
indicate that Ly9 is a potential therapeutic target for the treatment of SjS.
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INTRODUCTION
Sjögren’s Syndrome (SjS) is a chronic autoimmune disease that affects the salivary and
lacrimal glands with progressive dryness of mouth and eyes (1). SjS is one of the most
prevalent systemic autoimmune diseases in the general population (2). It is more common
in middle-aged women, with a female/male ratio of 9:1. Patients with primary SjS suffer
from glandular disease alterations and develop moderate to severe systemic extraglandular
manifestations that affect other organs (3). SjS patients also have increased susceptibility to suffer
other autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematous (4).
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The pathophysiology of SjS is characterized by abnormal
lymphocyte infiltration around the glandular epithelial cells in
the lacrimal and salivary glands. This lymphocytic infiltration can
be also observed in other tissues such as the tubular epithelial cells
in the kidney or respiratory epithelia (5). SjS patients present anti-
nuclear autoantibodies such as anti-ribonuclearprotein Ro, and
elevated levels of rheumatoid factor that correlate with clinical
outcome (6, 7). Another hallmark of SjS is the B cell hyperactivity
characterized by the clonal expansion of marginal zone (MZ) B
cells. Increased numbers of MZ B cells, in spleen and salivary
glands, have been observed in several mouse models of SjS
(8). B cell hyperactivity, due to ongoing antigenic stimulation,
is initially polyclonal but can progress to monoclonal B cell
lymphoproliferation ultimately leading to B cell lymphoma
development. Accordingly, it is well known that SjS patients
have a significantly higher risk of developing lymphoproliferative
diseases, being the most common MZ B-cell lymphoma, which
is the most detrimental clinical complication of this disease
(9, 10). The current treatments aim to reduce symptoms of the
exocrinopathy as well as to control the extraglandular features of
the disease. However, at this stage, no disease-modifying drugs
have been shown to be effective for the treatment of SjS (11).
Ly9 (CD229, SLAMF3) is a member of the SLAM family
of cell surface receptors (12). It is present on all B and T
lymphocytes with very high expression levels on NKT cells
and MZ B cells (13, 14). Ly9 has four Ig-like domains
and a long cytoplasmic tail containing two ITIM motifs,
which are docking sites for the adapter molecule SAP and
tyrosine phosphatases such as SHP2 or SHIP-1 (15, 16). It
functions as a homophilic adhesion molecule and a signaling
inhibitory receptor (17). Moreover, aged Ly9-deficient mice
spontaneously develop features of systemic autoimmunity, such
as splenomegaly and the production of anti-nuclear, anti-dsDNA,
and anti-nucleosome autoantibodies, indicating that the Ly9 cell
surface receptor is involved in the maintenance of immune
cell tolerance (18). Recently, we have shown that antibody-
mediated targeting of Ly9 down-regulates B cell responses
and selectively depletes splenic MZ B and B1 cells (19). Ly9
antibody targeting induces a decrease in the expression of the
CD19 complex and down modulates the expression of several
adhesion molecules such as L-selectin (CD62L) and alfa4/beta7
integrin (19). Here, we explore the therapeutic potential of
Ly9 antibody targeting in the non-diabetic NOD.H-2h4 mice,
a mouse model of spontaneous autoimmunity mimicking SjS
(20).
Our results show that Ly9 antibody targeting selectively
depletes MZ, B1 and germinal center (GC) B cells in lymphoid
tissues, and decreases lymphocyte infiltration in the salivary
glands and kidney by modulating B cell activation and trafficking
of T and B cells to inflammation sites.
MATERIALS AND METHODS
Mice
NOD.H-2h4 (NOD.Cg-H2h4/DilTacUmm) mice were purchased
from Jackson Laboratory and breed under specific pathogen free
conditions at the animal house facility from Faculty of Medicine,
University of Barcelona. 12 and 24-weeks-old female mice were
used for the experiments. All 24-weeks-old NOD.H-2h4 female
mice at this age are known to have salivary gland infiltrates
and autoantibodies such as anti-Ro and anti-dsDNA (21).
Mice experiments were performed according to the European
Community Directive 2010/63/EU and Spanish legislation (Real
Decreto 53/2013, BOE-A-2013-101337) regulating the protection
and usage of laboratory animals. Experimental procedures were
approved by the Ethics Committee for Animal Experiments
(CEEA) of the University of Barcelona.
In vivo Treatment With Anti-Ly9 mAb
Two treatment approaches were assessed; a therapeutic and a
preventive. For the therapeutic approach, 24-weeks-old female
NOD.H-2h4 mice were injected with two i.p. doses of 250 µg of
endotoxin-free Ly9.7.144 (IgG1) mAb or isotype control (IgG1)
in sterile PBS. Ly9.7.144 mAb was generated in our lab (22). The
two doses were separated by 3 weeks, since we had previously
observed that a single dose of 250 µg was able to maintain its
biological effect for a period of at least 26 days (19). After the
6-week treatment period, mice were euthanized and plasma and
organs were collected. For the preventive approach, 12-week-old
female NOD.H-2h4 mice a single i.p. dose of 250 µg of Ly9.7.144
mAb or isotype control for 2 weeks was given. At 14 weeks mice
were euthanized for plasma and organs collection.
Cell Isolation
Splenocytes and lymph nodes cell suspensions were obtained by
manual disaggregation and then treated with red blood cell lysis
buffer (0.15M NH4Cl, 0.01M Tris HCL), washed and incubated
in 20% heat-inactivated rabbit serum before being stained with
fluorophore-labeled antibodies. Cell counts were determined by
using PerfectCountTM microspheres (Cytognos). Salivary Gland
cell suspensions were obtained by gently chopping the organ and
incubating it in RPMI 3% FBS with 0.0625 mg/ml of collagenase
(Sigma) for 30min at 37◦C. Digestion was stopped by adding
RPMI 5mM EDTA. Then samples were filtered through a 70µm
cell strainer (Biologixs) and processed as described above. Bone
marrow cell suspensions were obtained by perfusion of femur
with complete RPMI using insulin syringes and processed as
splenocytes mentioned above.
Flow Cytometry
Cell suspensions from spleen, lymph nodes, and salivary glands
were incubated with the fluorophore-labeled antibodies for
45min on ice. For intracellular labeling cells were first labeled
with surface antibodies and then fixed/permeabilized with the
Foxp3 staining buffer set (eBioscience) and finally stained
with antibodies against intracellular antigen. The anti-mouse
monoclonal antibodies B220 (RA3-6B2), CD19 (6D5), CD5 (53-
7.3), CD138 (281-2), CD3 (145-2C11), CD4 (GK1.5), CD8 (53-
6.7), CD3 (17A2), Ly9 (Ly9ab3), integrin beta 7 (FIB504), and
CD45 (30-F11) were purchased from BioLegend; GL7 (GL-7),
T-Bet (eBio4B10), PLZF (Mags.21F7), CD62L (MEL-14) and
CD93 (AA4.1) were from eBioscience; CD23 (B3B4), CD95 (Jo2),
RORγT (Q31-378), CD44 (IM7), and CD45RB (16A) were from
BD Bioscience; CD49d (R1-2) was from Milteny Biotech; and
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goat anti-mouse IgMpolyclonal antibody from Southern Biotech.
Finally, PBS57-loaded mCD1d tetramer was kindly provided by
the NIH Tetramer Core Facility. Data were acquired with LSRII
Fortessa or FACSCanto II flow cytometers (BD Biosciences) and
analyzed with FlowJo vX.0.7 (Tree Star, Inc) software. Flow
cytometry experiments were performed as described (23).
Ly9 Receptor Occupancy
Antibody occupancy of Ly9 receptor was performed by a flow
cytometric assay with mAb Ly9ab3-APC (14) from BioLegend.
This mAb recognizes the same epitope as Ly9.7.144. Thus, Ly9
receptor cell membrane occupancy by Ly9.7.144 mAb blocks the
binding of Ly9ab3-APC (Supplemental Figure 1). In order to
guarantee the persistence of the biological effects of the mAb
treatment, mice that had<50% of Ly9 receptor occupancy, at the
endpoint, were excluded from the study.
Anti-nuclear Autoantibody (ANA) Detection
by Immunofluorescence
Briefly, Hep-2 cells were fixed with PBS 4% formaldehyde and
permeabilized with PBS 0.05% Triton. Then, cells were blocked
with PBS 5% FBS 20% rabbit serum and incubated with serial
dilutions of the sera starting at 1:40 dilution. To detect IgG ANAs
an anti-mouse IgG Fc FITC antibody (Jackson Immunoresearch)
was used. Finally, slides were visualized on a fluorescenceNIKON
e600 microscope and titers were determined by two different
investigators.
Autoantibody Detection by ELISAs
Briefly, high binding plates (Costar) were coated with the
following antigens diluted in PBS: 3µg/ml of IgG to detect
IgM rheumatoid factor antibodies; 3µg/ml of anti-mouse IgG
(Sigma M2650) to detect total IgG; 3µg/mL of F(ab’)2 fragments
anti-mouse IgM to detect total IgM; 10µg/ml of calf thymus
dsDNA (Sigma) to detect anti-dsDNA IgG antibodies and
10µg/ml of Ro52 (Sigma) antigen to detect anti-Ro52 antibodies.
Purified antibody anti-dsDNA (Clone HspS22, Immunotools)
was used as standard. Samples were diluted 1/100 for anti-
dsDNA, 1/40 for rheumatoid factor, 1/40000 for total IgG,
1/5000 for total IgM and 1/20 for anti-Ro52 followed by
the next secondary antibodies: Horseradish peroxidase (HRP)
conjugated goat anti-mouse IgG (Sigma; dilution 1/2000) for
anti-dsDNA, total IgG and anti-Ro52; Biotin rat anti-mouse
IgM (BD Pharmingen; dilution 1/2000) and HRP-conjugated
streptavidin (Roche; dilution 1/5000) for IgM rheumatoid factor
and total IgM. Plates were developed with TMB substrate (BD
Bioscience) and read with an Epoch plate reader at 450–570 nm.
Histology and Immunohistochemistry
Mice were euthanized at indicated time-points, and salivary
glands and kidneys were immediately collected. Organs were
fixed in PBS 4% formaldehyde overnight. After fixation tissues
were embedded in paraffin and 5µm sections were obtained.
Tissue sections were then immersed in xylene and dehydrated
in ethanol. Staining was performed with hematoxylin and eosin
(H&E) following standard protocols. Sections were visualized
at 10× magnifications using Nikon ECPLISE Ti-S microscope.
Areas were manually localized and contoured as well as
automatically calculated by using NIS-Elements software. Kidney
H&E sections were assessed, blindly, by a veterinary pathologist.
Fixed paraffin-embedded salivary gland tissue sections were
immersed in xylene and dehydrated in ethanol. After antigen
retrieval, tissue sections were blocked with PBS 5% FBS and
then primary antibodies were incubated at 4◦C overnight.
The mAbs rabbit anti-CD3 (D4V8L; dilution 1/100), CD4
(D7D2Z; dilution 1/100) and CD8 (D4W2Z; dilution 1/400)
were purchased from Cell Signaling; rat anti-B220 (RA3-6B2;
dilution 1/100) was from BD Bioscience. After the incubation
of primary antibodies, the endogenous biotin was blocked with
the Avidin/Biotin blocking kit SP-2001 (VectorLabs) following
manufacturer’s protocol and secondary antibodies were applied:
anti-rabbit-biotin (dilution 1/200) and anti-rat FITC (dilution
1/100; Jackson Immunoresearch) were used to detect antigen
binding. Streptavidin-A555 (dilution 1/2000) was purchased
from Roche. Finally, samples were mounted with mounting
media (PBS 10%Glycerol). Samples were visualized at 4, 10 and
20×magnifications using Nikon e600 microscope.
Splenocyte Migration Cell Adoptive
Transfer Experiment
Thirty-week-old NOD.H-2h4 mice were treated with either
Ly9.7.144 or isotype control antibodies for 24 h. Isolated
splenocytes from anti-Ly9 treated mice were labeled with 5µM
CFSE (Molecular Probes), whereas isotype control mice were
labeled with 20µM CMAC (Molecular probes). After staining,
cells were mixed together and a total of 20 × 106 cells (initial
ratio of 1:1 of CFSE/CMAC cells) were i.v. administrated into an
age-matchedNOD.H-2h4 mice. Finally, 24 h after transferring the
cells, mice were euthanized and spleen, lymph nodes (mesenteric,
inguinal and submandibular) and salivary glands were removed
and processed, as described in sections above, and the ratio
between CFSE/CMAC positive cells within each organ was
established.
Statistical Analysis
Differences between groups means or individual values were
assessed either by unpaired or paired two-tailed Student’s
t-tests. Two-tailed p-values < 0.05 were considered statistically
significant. All statistical analyses were performed using
GraphPad Prism software version 6.01.
RESULTS
Selective Depletion of Splenic MZ, B1, and
GC B Cells After Administration of Anti-Ly9
mAb in Mice With Sjögren’s Syndrome
Twenty-four-week-old NOD.H-2h4 female mice, which
spontaneously develop a SjS-like disease, were injected
with agonistic anti-Ly9 mAb Ly9.7.144 (19). After 6-week
treatment, mice were euthanized and lymphocyte subsets from
several lymphoid organs were analyzed by flow cytometry.
The injection of Ly9.7.144 mAb dramatically decreased the
percentage and absolute numbers of MZ B cells in the spleen
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(Figures 1A,B). Concomitantly, an increment in the number
of follicular B cells was observed (Figure 1C). The total
number of B cells was increased (15.7 ± 1.06 × 106 vs. 31.1
± 5.07 × 106; p = 0.0014; Isotype vs. anti-Ly9-treated mice,
respectively).
Interestingly, the treatment with Ly9.7.144 induced
a significant reduction of GC B cells (Figures 1D,E).
Moreover, B1 B cells were also reduced, by a 50%, in
percentage and numbers (Figures 1F,G), primarily due
to the decrease in the number of B1a cells. This data
shows that Ly9.7.144 treatment is able to target key
subsets of splenic B cells strongly related to SjS pathology
development and maintenance. Note that the total
number of B cells before treatment were lower than those
previously reported (24) but identical to those found by
others (25), probably due to difference in cell counting
techniques.
The Splenic T Cell Compartment of
NOD.H-2h4 Is Modestly Disturbed by
Ly9.7.144 Injection
A significant reduction was observed in percentage of splenic
naïve CD8+ T cells but this reduction was not reflected in
absolute numbers (Supplemental Figures 2A,B) since the total
number of T cells was augmented (15.82 ± 1.1 × 106 vs.
23.45 ± 1.9 × 106; p = 0.0016; Isotype vs. anti-Ly9-treated
mice, respectively). This increase was due to an increase of both
memory CD4+ and CD8+cells (Supplemental Figures 2A,B).
The percentages of CD3+ T cells were not affected by anti-Ly9
treatment (data not shown).
The effect of Ly9.7.144 injection on iNKT cells was also
analyzed. We observed a reduction in percentage of total iNKT
cells but not in absolute numbers (Supplemental Figures 2C,D).
When we analyzed the specific subsets iNKT1, iNKT2 and
iNKT17, we could not appreciate any effect of Ly9.7.144 on their
FIGURE 1 | MZ, B1, and GC B cells are depleted by Ly9.7.144 administration in the spleen of SjS mice. Representative dot plots are shown for splenic MZ and
follicular B cells (A), GC B cells (D), and B1 B cell subsets (F) from female NOD.H-2h4 mice treated with Ly9.7.144 (right plots) or isotype control (left plots).
Percentage and absolute counts for the different cell subsets are shown: MZ B cells (B); follicular B cells (C); GC B cells (E) and B1 B cell subsets (G). Mice treated
with Ly9.7.144 mAb are represented as empty dots and mice treated with isotype control are represented as black dots. Results are expressed as mean ± SD.
** p < 0.01; ***p < 0.001; **** p < 0.0001 (unpaired two-tailed t-test). Data are pooled from three independent experiments.
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percentages or absolute numbers (Supplemental Figures 2E,F).
These results indicate that anti-Ly9 antibody administration had
a rather mild effect on T cell subsets.
MZ B and Naïve T Cells Within
Submandibular Draining Lymph Nodes Are
Reduced by Ly9.7.144 Injection
High levels of MZ-like B cells within salivary gland draining
lymph nodes were observed (Figures 2A,B). These cells were
dramatically reduced after the administration of Ly9.7.144
antibody (Figures 2A,B). On the other hand, follicular B cells
were not altered in numbers (Figure 2C). Interestingly, we
observed a trend in decreased GC B cells from lymph nodes in
percentage and counts (Figures 2D,E; p = 0.0723 and 0.0707,
respectively). Mice treated with Ly9.7.144 presented a reduction
in absolute numbers of lymphocytes (4.69 ± 0.77 × 106 vs. 2.10
± 0.35 × 106; p = 0.0245; Isotype vs. anti-Ly9-treated mice,
respectively). Total T cells and, specifically, naïve CD4+ and
CD8+ T cells were also reduced as well as memory CD4+ T
cells (Figures 2F–H). Thus, anti-Ly9 antibody does not have a
FIGURE 2 | MZ and GC B cells, and naïve T cells are diminished by Ly9.7.144 injection in the draining lymph nodes of SjS mice. Representative dot plots are shown
for draining lymph nodes MZ and follicular B cells (A), GC B cells (D) and CD4+ or CD8+ memory and naïve T cells (F) from female NOD.H-2h4 treated with
Ly9.7.144 (right plots) or isotype control (left plots). Percentage and absolute counts for the different cell subsets are shown: MZ B cells (B); follicular B cells (C); GC B
cells (E); CD3+, CD4+, and CD8+ cells (G) and CD4+ or CD8+ naïve and memory T cells (H; percentages are from parental CD3+CD4+ or CD3+CD8+ as
specified). Mice treated with Ly9.7.144 mAb are represented as empty dots and mice treated with isotype control are represented as black dots. Results are
expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001 (unpaired two-tailed t-test). Data are pooled from three independent experiments.
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dramatic effect on T cells as compared to the B cells in this SjS
model.
Salivary Gland of SjS Mice Show Reduced
Lymphocyte Infiltrates After Anti-Ly9
Administration
The total area of infiltrating cells in the salivary glands, which
is the main target organ of SjS, was significantly decreased
in anti-Ly9 treated mice (Figures 3A–D). This reduction was
accompanied by a trend reduction of the foci numbers,
indicating that the anti-Ly9 treatment was able to reduce
the size of this lymphocyte aggregates but not completely
eliminate lymphocyte infiltration (Figure 3C). To better study
the lymphocyte subpopulations present in the salivary gland
infiltrates, we analyzed paraffin-embedded tissue sections by
immunofluorescence. Isotype-treated mice showed larger foci
formed by T cells surrounded by B cells (Figures 3D, 4A–C). A
reduction of both T and B cell infiltrates of mice receiving anti-
Ly9 was observed when compared to those mice getting isotype
control (Figure 4).
To further characterize the reduction of the B lymphocyte
infiltrates of treated mice, we performed a flow cytometric
analysis of lymphocytes isolated from collagenase treated tissue.
Our results showed a reduction of B cells (CD45+B220+)
and specifically of B cells with a MZ-like phenotype
(CD45+B220+CD21+CD23low), which are predominant in the
inflamed salivary gland (Supplemental Figures 3A–D). Taken
together, these results show an important anti-inflammatory
effect of anti-Ly9 treatment.
FIGURE 3 | Mice receiving Ly9.7.144 show a reduction in lymphocyte infiltrates area in the inflamed salivary glands of SjS mice. Representative foci from isotype
control (left) or anti-Ly9 (right) treated NOD.H-2h4 mice found in H&E and immunofluorescence (B220 is shown in green and CD3 in red) staining are shown (A,D).
Total area of infiltrating cells (B) and foci number (C) were calculated from H&E staining of salivary gland paraffin-embedded tissue sections. Three consecutive tissue
sections were analyzed per mice to determine foci number. Dotted lines contouring infiltrating areas are indicated with black arrows. The foci was defined as the
presence of >50 infiltrating leukocytes in continuum space. Results are expressed as mean ± SD. *p < 0.05 (unpaired two-tailed t-test). Data are pooled from four
independent experiments.
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FIGURE 4 | The architecture of salivary gland cell infiltrates is notoriously affected in anti-Ly9-treated SjS mice. Representative immunofluorescence of salivary gland
cell infiltrates from anti-Ly9 (right) or isotype control (left) treated NOD.H-2h4 mice. The following two color colocalizations at 10× and 20× augmentations are shown:
B220 [green] + CD3 [red] (A); B220 [green] + CD4 [red] (B) and B220 [green] + CD8 [red] (C).
Ly9 Targeting Reduces Lymphocyte
Migration Into Inflamed Salivary Glands
We previously reported that anti-Ly9 treatment was able to
down-regulate several adhesion molecules, including L-selectin
(CD62L) and integrin alfa4/beta7, in Balb/c mice (19). Here, we
observed that Ly9 targeting also induced an identical effect on
NOD.H-2h4 mice T and B lymphocytes (Figure 5A). However,
we do not exclude that the expression of other lymphocyte
adhesion molecules may be affected. To elucidate if the down-
modulation of these adhesion molecules could contribute to the
observed reduction of the salivary gland lymphocyte infiltration,
we performed an in vivo two-color lymphocyte migration
experiment. We transferred equal numbers of CMAC-labeled
splenic lymphocytes from isotype treated mice together with
CFSE-labeled splenic lymphocytes from anti-Ly9 treated mice
into NOD.H-2h4 recipients. After 24 h, the ratio of transferred
lymphocytes was analyzed in different tissues. Our results showed
that lymphocytes from anti-Ly9 treated mice were much less
efficient reaching salivary gland and mesenteric lymph nodes
than their isotype treated counterparts, whereas migration into
other organs such as spleen, inguinal, and draining lymph nodes
was not affected (Figures 5B,C). We could also observe that
both B and T cells were equally hindered in their ability to
migrate to salivary gland and mesenteric lymph nodes after anti-
Ly9 administration (Figures 5D,E). Differences between T and
B cells migrating to the inguinal lymph node may be explained
by the lower expression of L-selectin on the surface of B cells as
compared to T cells.
Early Anti-Ly9 Injection Prevents Onset of
Salivary Gland Cell Infiltrates
In order to explore if the ability of Ly9.7.144 mAb to reduce
lymphocyte trafficking could affect infiltration into the salivary
gland, we treated 12-weeks-old female NOD.H-2h4 mice. At
this age NOD.H-2h4 mice do not present cellular infiltrates
(Figures 6A,B). Twelve-week-old NOD.H-2h4 mice treated with
a single injection of anti-Ly9 for 2 weeks remained without
cell infiltrates, whereas most of the mice receiving the isotype
control showed several foci and an increased infiltration area
(Figures 6A,B). These results strongly suggest that the reduction
in lymphocyte migration is a contributing factor to the decline in
salivary gland inflammation induced by anti-Ly9 treatment.
Ly9.7.144 Treatment Ameliorates Kidney
Inflammation
Since kidney involvement is a frequent extraglandular
manifestation of primary SjS. We next analyzed if mAb
Ly9.7.144 could have an effect on kidney inflammation present
in NOD.H-2h4 mice. To do so, we analyzed paraffin-embedded
tissue sections of kidneys from treated mice and compared with
those receiving the isotype control. Mice receiving anti-Ly9 mAb
presented a dramatic reduction of the total area of cell infiltrates
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FIGURE 5 | Monoclonal antibody Ly9.7.144 impairs the ability of lymphocytes to migrate into the inflamed salivary glands and mesenteric lymph nodes of SjS mice.
Percentages of relative MFI from the spleen of Ly9.7.144-treated mice for 16 h over the mean MFI from isotype-treated mice are shown for the different surface
proteins (A). Black dots indicate that MFI values were from pre-gated T cells and empty squares indicate that MFI values were from pre-gated B cells. Results are
expressed as mean ± SD. ***p < 0.001; ****p < 0.0001 (unpaired two-tailed t-test). Data is from one independent experiment. Representative dot plots for migrating
splenocytes into spleen, lymph nodes and salivary gland from age-matched NOD.H-2h4 recipient mice are shown (B). Transferred splenocytes from Ly9.7.144-treated
NOD.H-2h4 mice were stained with CFSE cell tracker. Transferred splenocytes from istoype-treated NOD.H-2h4 mice were stained with CMAC cell tracker. Same cell
numbers from each mouse were mixed and i.v. administrated. After 24 h the CFSE+/CMAC+ ratio was calculated for each organ. The ratios of total transferred
splenocytes are shown (C) as also the ratio of transferred B220+ (D) and CD3+ (E) cell subsets. A dashed line indicates ratio value one. Results are expressed as
mean ± SD. **p < 0.01; ****p < 0.0001 (unpaired two-tailed t-test). Data is pooled from three independent experiments (C). Data is from one independent experiment
(D,E). To be able to see the B220+ and CD3+ transferred cell subsets migrating into the salivary gland, the three salivary glands from the recipient mice were pooled
in one unique sample acquisition (D,E).
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FIGURE 6 | Early administration of anti-Ly9 prevents the apparition of salivary
gland cell infiltrates. The foci numbers are compared (A) between untreated
12-weeks-old female NOD.H-2h4 (black squares) and 14-weeks-old female
NOD.H-2h4 mice that received a single dose of Ly9.7.144 (empty dots) or
isotype control (black dots) for a period of 2 weeks. Same comparison is made
with the total area of infiltrate (B). The foci was defined as the presence of >50
infiltrating leukocytes in continuum space. Results are expressed as mean ±
SD. (unpaired two-tailed t-test). Data is from one independent experiment
(A,B).
as compared to the control group (Figures 7A,B). Moreover,
anti-Ly9 treated mice had significantly fewer numbers of foci
(Figure 7C). In contrast, no difference between mice groups in
percentage of glomerulosclerosis (obsolete glomeruli per total
glomeruli) could be observed (data not shown).
Ly9.7.144 Administration Affects
Autoantibodies Production
We next sought to analyze if anti-Ly9 injection was able to
affect anti-nuclear antibodies titers (Figure 8A). A significant
decrease in the titers of ANAs was detected in mice receiving
Ly9.7.144, whereas no significant change could be observed
in the mice injected with the control mAb (Figures 8A,B).
Although anti-Ly9 treatment was not able to reduce the levels
of anti-dsDNA autoantibodies, these mice did not increase the
levels of this autoantibody as observed in the mice treated with
the isotype control (Figure 8C). Rheumatoid factor levels were
also significantly affected by anti-Ly9 treatment (Figure 8D). In
contrast, anti-Ly9 treatment was not able to reduce anti-Ro52
autoantibodies (Figure 8E). These data collectively show that
anti-Ly9 is able to have an impact on autoantibody production.
Treatment With Anti-Ly9 Induces a Slight
Decrease in Plasma Cell Numbers
Since Ly9 is also expressed on plasma cells, we analyzed if
these cells were affected by anti-Ly9 injection. Splenic plasma
cell numbers defined as CD19−IgM−B220dimCD138hi showed
a trend to decrease (Figures 9A,B). However, total serum IgG
and IgM levels were not disturbed (Figures 9C,D). Finally, we
also analyzed the plasma cell numbers in the bone marrow
defined as IgD−IgM−B220dimCD138hi after a single injection
of Ly9.7.144 for 2 weeks. As with splenic plasma cells, we
observed a trend to decrease in numbers (Figures 9E,F). Taken
together, these data suggest that anti-Ly9 treatment impairs
autoantibody production (Figure 8) without causing general
immunosuppression (Figure 9).
DISCUSSION
The results of this study demonstrate that antibody targeting of
the cell surface molecule Ly9 (CD229) can restrain spontaneous
autoimmune disease in amousemodel of SjS.We have previously
demonstrated that treatment of mice with Ly9.7.144, an agonistic
mAb directed against mouse Ly9, had a dramatic effect on splenic
MZ and B1 B cells without significantly affecting the number
of conventional B cells (19). Since these two subsets of innate-
like B cells have been postulated to be essential players in the
pathogenesis of SjS in both humans and mice (8, 11, 26–28), we
decided to test the hypothesis that injection with this mAb may
be able to hinder the development of autoimmunity in NOD.H-
2h4 mice. Similar to SjS patients, these mice develop spontaneous
exocrine gland disease, but in contrast to NODmice, they do not
develop diabetes (20). Moreover, these mice do not only exhibit
lymphocytic salivary gland infiltration, but also extraglandular
inflammation, such as renal inflammation, mimicking systemic
disease manifestations seen in patients (20). In addition, these
mice develop autoantibodies to antinuclear antigens such as
double-stranded DNA and anti-Ro antibodies, and rheumatoid
factor preceding the development of lymphocytic infiltration in
the salivary glands (21). In this study, we have injected NOD.H-
2h4 mice at the age of 24-weeks, when all female mice are
known to present salivary gland infiltration, with the mouse anti-
mouse Ly9 agonistic mAb, Ly9.7.144. Our results demonstrate
that splenic MZ and B1 B cells were diminished after anti-Ly9
mAb injection. In contrast, the number of conventional follicular
B cells was found to be increased. MZ and B1 B cells are believed
to be responsible for production of autoantibodies to nuclear
antigens and other self-antigens, leading to immune complex
deposition in tissues (29). It is well known that a high proportion
of polyreactive innate-like B cells, such as MZ B cells and B-
1 B cells, are reactive with self-antigens. Improper control by
immune tolerance mechanisms drives these B cell subsets to
produce pathogenic autoantibodies (30). However, experiments
with several mouse models of SjS, including NOD.H-2h4 mice,
indicate that the major pathological function of MZ and B1 B
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FIGURE 7 | Mice receiving anti-Ly9 treatment show a reduction in renal tubular epithelium infiltrates in SjS mice. Representative foci from anti-Ly9 (right) or isotype
control (left) treated mice found in kidney H&E staining are shown (A). Total area of infiltrating cells (B) and foci number (C) were calculated from H&E staining of kidney
paraffin-embedded tissue sections of NOD.H-2h4 mice. Mice treated with Ly9.7.144 mAb are represented as empty dots and mice treated with isotype control are
represented as black dots. Dotted lines contouring infiltrating areas are indicated with black arrows. The foci was defined as the presence of >50 infiltrating leukocytes
in continuum space. Results are expressed as mean ± SD. **p < 0.01 (unpaired two-tailed t-test). Data is from one independent experiment (B,C).
cells is not autoantibody production but T cell activation induced
by antigen presentation to T cells and cytokine secretion. MZ
B cells have been demonstrated to have the potential to break
tolerance to autoantigens by virtue of their capacity to very
efficiently present peptides to self-reactive T cells (31). Antigen
presentation by B cells is required for development of several
spontaneous autoimmune diseases and this is the reason why B
cell depletion treatments work in diseases, such as rheumatoid
arthritis or multiple sclerosis, where autoimmunity is mainly
driven by T cells (32). Interestingly, splenic GC B cells were also
significantly decreased in anti-Ly9 treated mice, despite normal
or even increased numbers of follicular B cells. We speculate
that the lower percentage of GC B-cells is a consequence of the
reduced numbers of MZ that are known to carry and present
antigens to GC B-cells (33). Thus, it is not surprising that
splenectomized and B cell-deficient mice do not develop SjS (20).
Moreover, elimination of spontaneous GC in spleens of young
NOD.H-2h4 mice, by blockade of CD40 ligand, abolished SjS
development (34). Therefore, early failure of self-tolerance in the
spleen has been proposed to be the initial trigger of the disease.
Later in life, this altered response would then be amplified in
the gland tissues resulting in disease progression. Importantly,
anti-Ly9 injection affected three populations of B cells (MZ, B1
and GC) that have been shown to be more resistant to depletion
with CD20 antibodies (35). It is currently unclear if the MZ
compartment can be (fully) restored after anti-Ly9 treatment
cessation. Determining how anti-Ly9 influences the long-term
homeostasis of this subset will be crucial before extrapolating
the treatment to SjS patients. Interestingly, the number of T
cells was only mildly affected after anti-Ly9. Although we cannot
exclude a direct effect of anti-Ly9 administration on the T cells,
the decrease in T cell numbers looks reminiscent to that observed
after CD20 treatment, indicating that B cells are key for the
maintenance of T cell homeostasis (35).
Lymph node MZ-like B cells, also known as nodal MZ, are
very infrequent in normal mice but present in autoimmune
mice (31). Importantly, these cells are expanded following
immunization with autoantigens and can efficiently present
these autoantigens to T cells inducing their proliferation (31).
Here, we provide evidence that the number of nodal MZ B
cells was diminished by anti-Ly9 injection in the draining
submandibular lymph nodes probably contributing to the
decrease in autoimmune response in the treated mice.
SjS is considered as an autoimmune epithelitis since the
lymphocytic infiltrates are found in the epithelial tissues (5).
The histological hallmark of both glandular and extraglandular
manifestations of SjS is the periepithelial lymphocytic infiltration,
characterized by ectopic clusters of T and B cells dominated by
CD4T cells. Chronic inflammation does not only affect epithelial
function but also contributes to the autoimmune process by the
activation and differentiation of lymphocytes with autoreactive
potential within the target tissues (36). Here we demonstrate that
anti-Ly9 treatment is able to reduce lymphocyte infiltration in
salivary glands. Both T and B cells were reduced in the infiltrated
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FIGURE 8 | Ly9.7.144 mAb is capable to affect serum autoantibody levels in SjS mice. Photographs of representative ANAs titers (A) from pre- (upper panels) and
post- (down panels) treatment either with isotype (left panels) or Ly9.7.144 (right panels) mAb are shown. ANAs IgG titers (B), anti-dsDNA IgG (C), rheumatoid factor
IgM (D), anti-Ro52 IgG (E) autoantibody levels are presented from sera of female NOD.H-2h4 mice previous to treatment (24-weeks-old) and after treatment
(30-weeks-old). Mice treated with Ly9.7.144 mAb are represented as empty dots and mice treated with isotype control are represented as black dots. To exemplify
ANAs the same titer was used at 40 magnifications as specified at the upper right corner of each photograph. Results are expressed as paired values
(B–E).*p < 0.05; **p < 0.01 (paired two-tailed t-test). Data are pooled from four independent experiments.
tissue. Our results using a two-color migration assay indicated
that anti-Ly9 treated splenic lymphocytes deficiently migrated to
the salivary glands. We also observed a dramatic decrease in the
migration to the mesenteric lymph nodes without any significant
alteration in the migration to the spleen or other lymph nodes.
This pattern of alteredmigration is characteristic of the combined
deficiency of L-selectin and integrin beta7 (37). Also, it is well
known that alfa4/beta7 integrins are critical for migration of
lymphocytes through high endothelial venules associated to
mucosa (mesenteric lymph nodes) or tissues with inflammation
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FIGURE 9 | Treatment with anti-Ly9 does not cause general immunosuppression. Representative dot plots of B220 and CD138 are shown for plasma cells from
splenocytes gated on CD19− IgM− (A) or bone marrow cells gated on IgD− IgM−. (E) from 30-weeks-old (A–D) or 14-weeks-old (E,F) female NOD.H-2h4 mice
treated with two doses (A–D) or a single dose (E,F) of Ly9.7.144 (right plots) or isotype control (left plots). Absolute counts for the different plasma cells from spleen
(B) and bone marrow (F) are shown. Total levels of IgG (C) or IgM (D) are presented from sera of female NOD.H-2h4 mice previous to treatment (24-weeks-old) and
after treatment (30-weeks-old).Mice treated with Ly9.7.144 mAb are represented as empty dots and mice treated with isotype control are represented as black dots.
Results are expressed as mean ± SD. (unpaired two-tailed t-test). Data are pooled from three independent experiments (A–D) or from one experiment (E,F).
(38). We speculated that the down-modulation of these two key
adhesion molecules by anti-Ly9 affects lymphocyte trafficking,
hindering their migration. This could explain the decreased
numbers of both T and B lymphocytes in the draining lymph
nodes and salivary gland while increasing their accumulation
in the spleen. Therefore, targeting of Ly9, by altering the
migration of lymphocytes, would prevent the local expansion
of autoreactive cells in sites of inflammation in non-lymphoid
tissues. Thus, our data point to a dual action of anti-Ly9
treatment, depleting B cells subsets and impacting lymphocyte
migration to the inflamed tissues.
Here, we also show that anti-Ly9 treatment was able to
significantly reduce renal extraglandular inflammation. Although
clinical manifestations of renal failure are observed in around a
10% of SjS patients, recent studies indicate that the prevalence
of renal involvement is much higher (39). Renal involvement in
primary SjS is the result of epithelial disease with a predominantly
lymphocytic infiltration resulting in tubulointerstitial nephritis
and glomerulopathy due to the deposition of immune complexes.
NOD.H-2h4 mice present both kidney alterations, but anti-
Ly9 treatment dramatically reduced tubulointerstitial infiltration
without a significant impact on altered glomerular structure.
This observation is consistent with the rather mild effect of Ly9
targeting on the autoantibody production.
Hypergammaglobulinemia and the presence of autoantibodies
are indicators of B cell hyperreactivity in SjS. Here, we observed
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a reduction of anti-nuclear antibodies and rheumatoid factor.
This reduction was very specific since total serum IgG and IgM
levels were not affected by anti-Ly9 injection (Figures 9C,D).
However, we could not observe a significant inhibition of anti Ro
autoantibody production.
In conclusion, our results show that Ly9.7.144 treatment
is able to target essential B cells subsets strongly related to
the development and maintenance of SjS pathology, and to
significantly reduce glandular and extragladular inflammation.
In contrast with B cell depletion therapies, such as CD20,
the selective deletion of MZ, B1 and GC B cells, with
minimal reduction of the conventional B- and T-lymphocyte
compartments, should be regarded as an attractive new
therapeutic option.
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